Sorrento Therapeutics has won the Frost & Sullivan 2010 Global Biopharmaceutical Emerging Company of the Year Award.

The company has made great strides in the human monoclonal antibodies (mAbs) market, worth nearly $30bn in 2009.

It has built one of the largest mAbs libraries, which contains a diverse collection of fully human and full-length mAbs that could be either commercialised or used for developing their own therapeutic candidates.

Sorrento has also developed a ribonucleic acid (RNA) transcription-based amplification technology called STI Technology, which has competitive benefits over traditional PCR-based amplification methods for constructing antibody libraries.

Frost & Sullivan industry analyst Arun A. K. said that, on top of this, Sorrento is making good progress in enhancing its visibility.

“It has hired an experienced business development professional from the antibody industry to promote and develop its business,” he said.

The Frost & Sullivan award is presented annually to a company that has emerged as a significant participant in the industry, based on factors including business development, competitive strategy, and leadership.